Scholars Central

Conference abstractPublished 16 Oct 2017

STVNa, A promising medicine for cardiac protection

Authors: Wen Tan

Guangdong University of Technology, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cardiac ischemia or hypertrophy involves multiple mechanisms and may lead to heart failure. Few medicines are now available for effective treatment. STVNa, derived from Stevia, has been shown beneficial effects in protection of acute cardiac ischemia. Our recent studies demonstrated that in animals with chronically coronary occlusion, consecutive oral treatment of STVNa significantly ameliorated the deterioration of cardiac function with reduced area of infarction and apoptosis. Long-term treatment of STVNa in Transverse Aortic Constriction (TAC) rats also protected the heart from fibrosis and hypertrophy remodeling and improved both cardiac systolic and diastolic function. In isoproterenol treated ventricular myocytes, STVNa reduced hypertrophy, inhibited the increases in cytosol calcium or ROS, and preserved contractility and mitochondrial membrane potential. Proteomic analysis, cell biochemistry and electrophysiological studies indicated that STVNa protected the heart against fibrosis and remodeling of metabolite and electrophysiology during ischemia and/or reperfusion injury or hypertrophy.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectCardiology
  • BylineArticles whose byline prints “Wen Tan”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels